![Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature - Agendia Inc. Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature - Agendia Inc.](https://agendia.com/wp-content/uploads/2014/04/2-EJC-Apr2014__evidence-asset-thumbnails.png)
Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature - Agendia Inc.
![PDF) External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | Anne Vincent-salomon - Academia.edu PDF) External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | Anne Vincent-salomon - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/86436036/mini_magick20220524-18718-tg1b1v.png?1653457246)
PDF) External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | Anne Vincent-salomon - Academia.edu
![Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet Oncology Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/b489dfca-6b93-4ab8-9a95-5f144863708c/gr1.jpg)
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet Oncology
![Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer - ScienceDirect Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1098301513016987-gr1.jpg)
Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer - ScienceDirect
External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | PLOS ONE
![Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline - Agendia Inc. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline - Agendia Inc.](https://agendia.com/wp-content/uploads/2019/08/2-JCO-Jun2019__evidence-asset-thumbnails.png)
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline - Agendia Inc.
![Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients | Scientific Reports Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-64005-4/MediaObjects/41598_2020_64005_Fig1_HTML.png)
Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients | Scientific Reports
![Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer](https://www.mdpi.com/cancers/cancers-14-05467/article_deploy/html/images/cancers-14-05467-g001.png)
Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
![Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific](https://www.thelancet.com/cms/attachment/81a58431-adc8-4407-bcd5-2eb77dd2162c/gr1.jpg)
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
![Machine learning to guide the use of adjuvant therapies for breast cancer | Nature Machine Intelligence Machine learning to guide the use of adjuvant therapies for breast cancer | Nature Machine Intelligence](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs42256-021-00353-8/MediaObjects/42256_2021_353_Fig1_HTML.png)
Machine learning to guide the use of adjuvant therapies for breast cancer | Nature Machine Intelligence
![Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE | npj Breast Cancer Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-022-00477-z/MediaObjects/41523_2022_477_Fig1_HTML.png)
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE | npj Breast Cancer
![An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom | British Journal of Cancer An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.bjc.6605283/MediaObjects/41416_2009_Article_BF6605283_Fig2_HTML.jpg)
An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom | British Journal of Cancer
![PDF) Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria PDF) Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria](https://i1.rgstatic.net/publication/285384258_Cost_effectiveness_of_personalized_treatment_in_women_with_early_breast_cancer_the_application_of_OncotypeDX_and_Adjuvant_Online_to_guide_adjuvant_chemotherapy_in_Austria/links/56ae287308aeaa696f2e9bf9/largepreview.png)
PDF) Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria
![Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study - The Lancet Oncology Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d9703228-fc3a-4361-8574-cece79e56c05/gr1.jpg)
Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study - The Lancet Oncology
![Risk for breast cancer recurrence as determined by Adjuvant! Online and... | Download Scientific Diagram Risk for breast cancer recurrence as determined by Adjuvant! Online and... | Download Scientific Diagram](https://www.researchgate.net/publication/43345489/figure/fig1/AS:276818583146501@1443010101386/Risk-for-breast-cancer-recurrence-as-determined-by-Adjuvant-Online-and-the-modified-risk.png)
Risk for breast cancer recurrence as determined by Adjuvant! Online and... | Download Scientific Diagram
![The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study | npj Breast Cancer The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00366-x/MediaObjects/41523_2021_366_Fig1_HTML.png)
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study | npj Breast Cancer
![Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer | Breast Cancer Research | Full Text Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fbcr3038/MediaObjects/13058_2011_2847_Fig1_HTML.jpg)
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer | Breast Cancer Research | Full Text
![Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1aaed949-5c4f-462b-9551-ec8e88b8e698/tbj.v26.6.cover.jpg?trick=1685361402961)